{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:55Z","timestamp":1791421135035,"version":"4.3.3"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejphar.2014.01.017","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T15:45:55Z","timestamp":1390232755000},"page":"133-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Kv7 channels as targets for anti-epileptic and psychiatric drug-development"],"prefix":"10.1016","volume":"726","author":[{"given":"Morten","family":"Grunnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Str\u00f8b\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hougaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle","family":"Christophersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.ejphar.2014.01.017_bib1","doi-asserted-by":"crossref","first-page":"30668","DOI":"10.1074\/jbc.M805216200","article-title":"Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence\/fluorescence resonance energy transfer and patch clamp analysis","volume":"283","author":"Bal","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2014.01.017_bib2","series-title":"GeneReviews\u2122 [Internet]","first-page":"1993","article-title":"KCNQ2-related disorders","author":"Bellini","year":"2010"},{"issue":"5349","key":"10.1016\/j.ejphar.2014.01.017_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.279.5349.403","article-title":"A potassium channel mutation in neonatal human epilepsy","volume":"279","author":"Biervert","year":"1998","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ejphar.2014.01.017_bib4","doi-asserted-by":"crossref","first-page":"e8251 1","DOI":"10.1371\/journal.pone.0008251","article-title":"The acrylamide (S)-2as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytes","volume":"4","author":"Blom","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejphar.2014.01.017_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/bph.12065","article-title":"The new KCNQ2 activator 4-chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential","volume":"168","author":"Boehlen","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2014.01.017_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000026602","article-title":"Linopirdine (DUP 996): cholinergic treatment of older adults using successive and non-successive tests","volume":"40","author":"B\u00f6rjesson","year":"2013","journal-title":"Neuropsychobiology"},{"issue":"4","key":"10.1016\/j.ejphar.2014.01.017_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ Kv7 potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.ejphar.2014.01.017_bib8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2014.01.017_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng0198-53","article-title":"A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family","volume":"18","author":"Charlier","year":"1998","journal-title":"Nat. Genet."},{"issue":"1-3","key":"10.1016\/j.ejphar.2014.01.017_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2013.03.039","article-title":"Characterization of a novel high-potency positive modulator of Kv7 channels","volume":"709","author":"Dalby-Brown","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2014.01.017_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbr.2009.09.040","article-title":"Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder","volume":"207","author":"Dencker","year":"2010","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/j.ejphar.2014.01.017_bib12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1460-9568.2010.07107.x","article-title":"M-type channels selectively control bursting in rat dopaminergic neurons","volume":"31","author":"Drion","year":"2010","journal-title":"Eur. J. Neurosci."},{"issue":"10","key":"10.1016\/j.ejphar.2014.01.017_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/humu.20375","article-title":"KCNQ4: a gene for age-related hearing impairment?","volume":"27","author":"Van Eyken","year":"2006","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.ejphar.2014.01.017_bib14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0091-3057(94)90267-4","article-title":"Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission","volume":"49","author":"Fontana","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2014.01.017_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fgene.2013.00054","article-title":"Dysfunction of the heteromeric Kv7.3\/Kv7.5 potassium channel is associated with autism spectrum disorders","volume":"4","author":"Gilling","year":"2013","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.ejphar.2014.01.017_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.ejphar.2014.01.017_bib17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/jpet.106.106757","article-title":"The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat","volume":"318","author":"Hansen","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1-3","key":"10.1016\/j.ejphar.2014.01.017_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2007.05.029","article-title":"The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine","volume":"570","author":"Hansen","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejphar.2014.01.017_bib19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1113\/jphysiol.2007.149450","article-title":"Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS","volume":"586","author":"Hansen","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2014.01.017_bib20","doi-asserted-by":"crossref","first-page":"D680","DOI":"10.1093\/nar\/gkn728","article-title":"IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels","author":"Harmar","year":"2009","journal-title":"Nucleic Acids Res. (Database issue)"},{"issue":"8","key":"10.1016\/j.ejphar.2014.01.017_bib21","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1529\/biophysj.106.101287","article-title":"Inactivation as a new regulatory mechanism for neuronal Kv7 channels","volume":"92","author":"Jensen","year":"2007","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.ejphar.2014.01.017_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35036198","article-title":"Neuronal KCNQ potassium channels: physiology and role in disease","volume":"2000","author":"Jentsch","year":"2000","journal-title":"Nat. Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.ejphar.2014.01.017_bib101","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/CIRCULATIONAHA.111.032136","article-title":"Downregulation of Kv7.4 channel activity in primary and secondary hypertension","volume":"124","author":"Jepps","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.01.017_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1152\/physiol.00031.2005","article-title":"The KCNQ1 potassium channel: from gene to physiological function","volume":"20","author":"Jespersen","year":"2005","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.ejphar.2014.01.017_bib24","unstructured":"J\u00f8rgensen, S., Jensen, M.L., Hougaard, C. Dyhring, T. Christophersen, P., Str\u00f8b\u00e6k D., 2011. Subtype-dependent potencies and mode-of-actions for the Kv7 positive modulators retigabine, ICA-27243, BMS-204352 and (S)-1. Society for Neuroscience Meeting. P139.01."},{"issue":"3","key":"10.1016\/j.ejphar.2014.01.017_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)80556-5","article-title":"KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness","volume":"96","author":"Kubisch","year":"1999","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejphar.2014.01.017_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.105.083923","article-title":"Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels","volume":"314","author":"Korsgaard","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2014.01.017_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1528-1167.2011.03364.x","article-title":"The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use","volume":"53","author":"Large","year":"2012","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ejphar.2014.01.017_bib28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/mol.108.049825","article-title":"Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention","volume":"74","author":"Mackie","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2014.01.017_bib103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/mol.58.2.253","article-title":"Modulation of KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine","volume":"58","author":"Main","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2014.01.017_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1476-5381.2010.01027.x","article-title":"Expression and function of the K+ channel KCNQ genes in human arteries","volume":"162","author":"Ng","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2014.01.017_bib108","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1124\/mol.61.4.921","article-title":"Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission","volume":"61","author":"Otto","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2014.01.017_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2009.08.071","article-title":"The KCNQ2\/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site","volume":"465","author":"Padilla","year":"2009","journal-title":"Neurosci. Lett."},{"issue":"18","key":"10.1016\/j.ejphar.2014.01.017_bib31","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1523\/JNEUROSCI.23-18-07227.2003","article-title":"KCNQ\/M currents in sensory neurons: significance for pain therapy","volume":"23","author":"Passmore","year":"2003","journal-title":"J. Neurosci."},{"issue":"35","key":"10.1016\/j.ejphar.2014.01.017_bib32","doi-asserted-by":"crossref","first-page":"15637","DOI":"10.1073\/pnas.0911294107","article-title":"Targeting the voltage sensor of Kv7.2 voltage-gated K+ channels with a new gating-modifier","volume":"107","author":"Peretz","year":"2012","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"issue":"Pt 6","key":"10.1016\/j.ejphar.2014.01.017_bib33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1242\/jcs.03396","article-title":"Requirement of subunit co-assembly and ankyrin-G for M-channel localization at the axon initial segment","volume":"120","author":"Rasmussen","year":"2007","journal-title":"J. Cell. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2014.01.017_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bbr.2008.12.027","article-title":"Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania","volume":"198","author":"Redrobe","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.ejphar.2014.01.017_bib111","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0028-3908(01)00029-6","article-title":"KCNQ4 channel activation by BMS-204352 and retigabine","volume":"40","author":"Schr\u00f8der","year":"2001","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.ejphar.2014.01.017_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00424-003-1116-x","article-title":"Voltage-independent KCNQ4 currents induced by (+\/\u2212)BMS-204352","volume":"446","author":"Schr\u00f8der","year":"2003","journal-title":"Pflugers Arch."},{"issue":"22","key":"10.1016\/j.ejphar.2014.01.017_bib36","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.1073\/pnas.0802805105","article-title":"Functional significance of axonal Kv7 channels in hippocampal pyramidal neurons","volume":"2008 105","author":"Shah","year":"2008","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.ejphar.2014.01.017_bib37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1124\/jpet.108.146944","article-title":"Antipsychotic-like effect of retigabine [N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission","volume":"328","author":"Sotty","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2014.01.017_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00011-013-0592-5","article-title":"Flupirtine, a re-discovered drug, revisited","volume":"62","author":"Szelenyi","year":"2013","journal-title":"Inflamm. Res."},{"issue":"Pt 1","key":"10.1016\/j.ejphar.2014.01.017_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1113\/jphysiol.2003.039842","article-title":"Effect of the KCNQ potassium channel opener retigabine on single KCNQ2\/3 channels expressed in CHO cells","volume":"549","author":"Tatulian","year":"2003","journal-title":"J. Physiol."},{"issue":"15","key":"10.1016\/j.ejphar.2014.01.017_bib40","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2174\/138161209788186326","article-title":"Kv7 channels as targets for the treatment of pain","volume":"15","author":"Wickenden","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.ejphar.2014.01.017_bib41","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.bmcl.2004.01.069","article-title":"(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons","volume":"14","author":"Wu","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2014.01.017_bib42","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nrd2983","article-title":"Voltage-gated potassium channels as therapeutic targets","volume":"12","author":"Wulff","year":"2009","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.ejphar.2014.01.017_bib43","unstructured":"Yu, H., Wu, M., Hopkins, C., Engers, J., Townsend, S., Lindsley, C., McManus, O.B., Li, M., 2010. A Small Molecule Activator of KCNQ2 and KCNQ4 Channels. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2011 Mar 29 [updated 2013 Feb 28]."},{"issue":"2","key":"10.1016\/j.ejphar.2014.01.017_bib44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0022-3565(24)37471-3","article-title":"Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine","volume":"285","author":"Zaczek","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:16:31Z","timestamp":1746116191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":48,"alternative-id":["S0014299914000181"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.017","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kv7 channels as targets for anti-epileptic and psychiatric drug-development","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}